{"cord_uid":"l951nirf", "sourcedb":"PMC", "sourceid":"PMC4858234", "divid":30, "text":"AcHERV-VLP immunized groups showed complete protection against live influenza virus challenge, while AcHERV-HA group showed 62.5% protection; as expected no protection was observed in the PBS group. Collectively, these results indicate that AcHERV-VLP provides better protection than AcHERV-HA, due to enhanced immunogenicity in both humoral immune response and cellular immune response (Fig 5B) .", "project":"cdlai_CORD-19", "denotations":[]}